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Sir, 
We report a case of Progressive Multifocal Leucoencephalopathy (PML) with 
Behcet’s Disease (BD), post immunomodulatory agents including rituximab and 
alemtuzumab. We studied our patient’s immunological response, contrasting 
with a cohort (n=27) of relapsing remitting multiple sclerosis (RRMS) patients. 
A 33 year-old, right-handed, woman with a 10-year prodrome, was diagnosed 
with BD in 2005.  She had one required criterion i.e. recurrent oral ulceration and 
3 minor criteria i.e. recurrent genital ulcers, uveitis confirmed by ophthalmology 
and characteristic skin disease.  She had multiple bowel resections; histology 
showed extensive ulceration with occasional vessels showing vasculitis. 
After an initial poor response to glucocorticoids, cyclosporine and thalidomide, 
she obtained partial remission with infliximab. Following an infusion reaction to 
infliximab, she had etanercept and then adalimumab for a further 10 months with 
partial disease control. In June 2006, she received four weekly doses of rituximab, 
and  further two doses in 2007,  with partial disease control. Meanwhile, she had 
multiple infections, recurrent acute kidney injury and required enteral and 
parenteral nutritional supplementation. In June 2007, she received alemtuzumab, 
60mg, which led to complete remission of Behcet’s disease symptoms.  
In May 2014, six months after her sixth alemtuzumab dose, she presented with 
a two-week history of focal neurological symptoms, indicating a left 
hemisphere pathology. MRI showed white matter signal abnormalities in the 
subcortical and juxtacortical areas of the left frontal lobe extending into the 
parietal subcortical white matter (Figure 1A). Cerebrospinal fluid was acellular, 
with normal constituents, negative cytology, negative fungal and bacterial 
cultures, negative viral PCRs for CMV, HSV and VZV. JC-virus PCR was 
positive in CSF and blood. Repeat imaging three weeks later (Figure 1B) 
showed progression of white matter changes. Treatment with intravenous 
immunoglobulin and mirtazapine was ineffective. She passed away two 
months later. An autopsy was not performed. 
Demyelinating lesions in neurological involvement with BD, tend to follow 
venular anatomy. They are characteristically seen in the parenchyma near the 
mesodiencephalic junction and alongside long tracts, often with acute contrast 
enhancement. The distinctive radiological lesions in our patient, with a positive 
JC-virus PCR, in the appropriate clinical context, fulfill diagnostic criteria for 
PML [1]. 
Amongst the treatments in our patient, anti-TNF therapies would confer a very 
low risk of PML [2]. Rituximab is a low risk drug, with calculated prevalence 
around 1/30,000, well below the lowest accurately estimable risk of 1/10,000.  
From 1997 to 2008, 52 patients with lymphoproliferative disorders, 2 with SLE, 1 
with rheumatoid arthritis, 1 with immune thrombocytopenia and 1 with 
autoimmune pancytopenia developed PML after rituximab [3]. Peripheral CD19 
cells remain undetectable for at least 4–5 months post rituximab; the timing of B-
cell recovery varies from 16 weeks to over 2 years [4].  
In our patient, 18 months following the last dose of rituximab and six months 
after the first course of alemtuzumab, CD19 counts indicated B-cell reconstitution 
(Supplementary Figure-S1B). However following the subsequent alemtuzumab 
courses, there was permanent B-cell depletion. This is an anomalous response to 
alemtuzumab which depletes both B and T-cells, with B-cells returning to greater 
than baseline values at 33 ± 6 months post-treatment [5]. CD4 T-cells remain 
depleted for an average of 61 months and CD8 cells for 30 months.  
There have been no cases of PML in RRMS on alemtuzumab.  4 other PML 
cases post-alemtuzumab have been reported with neoplasias.  
Interestingly, immune response in alemtuzumab treated RRMS patients differs 
from that in natalizumab, a high risk PML drug. The most prominent change 
post-natalizumab is an increase in CD34+ haematopoetic progenitor cells, along 
with pre-B and B-cells, due to impaired homing/adhesion in secondary lymphoid 
organs [6]. Also, majority of circulating B-cells post natalizumab are dominated 
by memory and marginal zone (MZ)-like B-cells thought to facilitate JCV 
activation [6]; whereas, post alemtuzumab, CD27- naïve B-cells form the majority 
of reconstituting B-cells (Supplementary Figure-S2E,F). Natalizumab also 
suppresses serum and CSF IgG and IgM levels over time, with decreased anti-
VZV antibody levels documented in post-natalizumab PML cases Contrastingly, 
humoral immunity to common viruses remains intact post alemtuzumab [7].Lee 
et al [8]report PML in a natalizumab-treated RRMS patient, who had a 
splenectomy in childhood. The circulating B-cell pool was significantly high in 
this case and dominated by memory and MZ-like B-cells. Unusually, PML 
occurred within a year of natalizumab treatment, raising the possibility that the B-
cell phenotype played a role in accelerated JCV reactivation.  
The lymphopaenia prior to rituximab and subsequent anomalous reconstitution 
in our patient, may have been a legacy of prior immunosuppressive therapy or 
indicate an idiosyncratic, innate or acquired immunodeficiency. Lymphocyte 
phenotyping showed a highly reactive immune system indicated by the subset of 
CD4 cells (HLADR+), with very poor CD19 cell reconstitution (Supplementary 
Figure-S1). These abnormal T and B-cell responses may have contributed to the 
development of PML. 
  
Key message 
Host factors play a key role in development of PML after immunomodulatory 
agents. 
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 Figure legend 
 
Figure 1 
Initial MRI (2A) shows T2/FLAIR signal intensity with corresponding reduced T1 signal (not 
shown here) intensity in the white matter with deterioration three weeks later (2B). 
 
 
 
 
 
 
 
 
 
